Cargando…

Antisense Oligonucleotides and Small Interfering RNA for the Treatment of Dyslipidemias

The burden of atherosclerotic disease worldwide necessitates implementing the treatment of its risk factors. Among them, hypercholesterolemia has a central role. In addition to conventional small organic compounds and the recently introduced monoclonal antibodies, new technologies are arising such a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gareri, Clarice, Polimeni, Alberto, Giordano, Salvatore, Tammè, Laura, Curcio, Antonio, Indolfi, Ciro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9267663/ https://www.ncbi.nlm.nih.gov/pubmed/35807171 http://dx.doi.org/10.3390/jcm11133884

Ejemplares similares

Lp(a) in the Pathogenesis of Aortic Stenosis and Approach to Therapy with Antisense Oligonucleotides or Short Interfering RNA
por: Di Costanzo, Assunta, et al.
Publicado: (2023)

Non-Coding RNAs: The “Dark Matter” of Cardiovascular Pathophysiology
por: Iaconetti, Claudio, et al.
Publicado: (2013)

Hindlimb Ischemia Impairs Endothelial Recovery and Increases Neointimal Proliferation in the Carotid Artery
por: Sorrentino, Sabato, et al.
Publicado: (2018)

Updates in Small Interfering RNA for the Treatment of Dyslipidemias
por: Carugo, S., et al.
Publicado: (2023)

A New Modality in Dyslipidemia Treatment: Antisense Oligonucleotide Therapy
por: Kim, Kyuho, et al.
Publicado: (2022)

Advances in the Design of (Nano)Formulations for Delivery of Antisense Oligonucleotides and Small Interfering RNA: Focus on the Central Nervous System
por: Mendonça, Monique C. P., et al.
Publicado: (2021)

Antisense Oligonucleotides and RNA Interference
por: Kher, Gitanjali, et al.
Publicado: (2011)

Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants versus Vitamin K Antagonist Oral Anticoagulants in Patients Undergoing Radiofrequency Catheter Ablation of Atrial Fibrillation: A Meta-Analysis
por: Santarpia, Giuseppe, et al.
Publicado: (2015)

Improved targeting of miRNA with antisense oligonucleotides
por: Davis, Scott, et al.
Publicado: (2006)

Empagliflozin prevents doxorubicin-induced myocardial dysfunction
por: Sabatino, Jolanda, et al.
Publicado: (2020)

Development of Antisense Drugs for Dyslipidemia
por: Yamamoto, Tsuyoshi, et al.
Publicado: (2016)

Impact of Percutaneous Mitral Valve Repair on Left Atrial Strain and Atrial Fibrillation Progression
por: Romano, Letizia Rosa, et al.
Publicado: (2023)

Antisense oligonucleotides in neurological disorders
por: Wurster, Claudia D., et al.
Publicado: (2018)

Molecular Mechanisms of Antisense Oligonucleotides
por: Crooke, Stanley T.
Publicado: (2017)

Antisense oligonucleotides: A primer
por: Scoles, Daniel R., et al.
Publicado: (2019)

Long-term outcomes of coronary artery bypass grafting versus stent-PCI for unprotected left main disease: a meta-analysis
por: De Rosa, Salvatore, et al.
Publicado: (2017)

First-in-human robotic percutaneous coronary intervention by the ROSES robotic system: a case report
por: Indolfi, Ciro, et al.
Publicado: (2023)

Small antisense oligonucleotides against G-quadruplexes: specific mRNA translational switches
por: Rouleau, Samuel G., et al.
Publicado: (2015)

Dual anti-thrombotic treatment with direct anticoagulants improves clinical outcomes in patients with Atrial Fibrillation with ACS or undergoing PCI. A systematic review and meta-analysis
por: De Rosa, Salvatore, et al.
Publicado: (2020)

The Future of Antisense Oligonucleotides in the Treatment of Respiratory Diseases
por: Ulanova, Marina, et al.
Publicado: (2012)

Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides
por: Juliano, Rudy, et al.
Publicado: (2008)

RNA-Based Therapeutics: From Antisense Oligonucleotides to miRNAs
por: Bajan, Sarah, et al.
Publicado: (2020)

Selective targeting of MYC mRNA by stabilized antisense oligonucleotides
por: Gill, Taylor, et al.
Publicado: (2021)

Delayed Sudden Radial Artery Rupture After Left Transradial Coronary Catheterization: A Case Report
por: Indolfi, Ciro, et al.
Publicado: (2015)

Hand Laser Perfusion Imaging to Assess Radial Artery Patency: A Pilot Study
por: Indolfi, Ciro, et al.
Publicado: (2018)

Multichannel Electrocardiograms Obtained by a Smartwatch for the Diagnosis of ST-Segment Changes
por: Spaccarotella, Carmen Anna Maria, et al.
Publicado: (2020)

A Tandem Oligonucleotide Approach for SNP-Selective RNA Degradation Using Modified Antisense Oligonucleotides
por: Magner, Dorota, et al.
Publicado: (2015)

Opportunities and challenges for antisense oligonucleotide therapies
por: Kuijper, Elsa C., et al.
Publicado: (2020)

Silencing Antibiotic Resistance with Antisense Oligonucleotides
por: Jani, Saumya, et al.
Publicado: (2021)

Drug Discovery Perspectives of Antisense Oligonucleotides
por: Kim, Yeonjoon
Publicado: (2023)

In-silico study of antisense oligonucleotide antibiotics
por: Chen, Erica S., et al.
Publicado: (2023)

Old unsolved problems: when and how to treat silent ischaemia
por: Indolfi, Ciro, et al.
Publicado: (2020)

Direct Oral Anticoagulants in Patients With Active Cancer: A Systematic Review and Meta-Analysis
por: Sabatino, Jolanda, et al.
Publicado: (2020)

Small Drugs, Huge Impact: The Extraordinary Impact of Antisense Oligonucleotides in Research and Drug Development
por: Quemener, Anais M., et al.
Publicado: (2022)

Long-term outcome of bioresorbable vascular scaffolds for the treatment of coronary artery disease: a meta-analysis of RCTs
por: Polimeni, Alberto, et al.
Publicado: (2017)

Reduction of Off-Target Effects of Gapmer Antisense Oligonucleotides by Oligonucleotide Extension
por: Yasuhara, Hidenori, et al.
Publicado: (2022)

Correction: A Tandem Oligonucleotide Approach for SNP-Selective RNA Degradation Using Modified Antisense Oligonucleotides
por: Magner, Dorota, et al.
Publicado: (2016)

Oligonucleotide antiviral therapeutics: Antisense and RNA interference for highly pathogenic RNA viruses
por: Spurgers, Kevin B., et al.
Publicado: (2008)

Towards next generation antisense oligonucleotides: mesylphosphoramidate modification improves therapeutic index and duration of effect of gapmer antisense oligonucleotides
por: Anderson, Brooke A, et al.
Publicado: (2021)

New treatments for myasthenia: a focus on antisense oligonucleotides
por: Angelini, Corrado, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_9d5ctasnm0onl4kgb3ia1j55jq